What Sotera Health (SHC) Said on Its Q3 Earnings Call
Sotera Health (SHC) reported Q3 earnings, noting softness in the European medical-device market. Sterigenics expects 6% constant-currency growth in Q4, while Nelson Labs saw 8.8% revenue growth. Nordion revenue fell 12.4% due to shipment timing. The company reaffirmed its 2026 outlook for 5.25% to 6.75% revenue growth and maintained its adjusted EBITDA forecast.
How this was made

The 30-second read
Why it matters
Near-term segment growth expectations were adjusted lower for Q4 (Sterigenics sequential growth) and Nordion revenue declined due to cobalt-60 harvest timing, but management reaffirmed full-year 2026 guidance and highlighted margin/leverage improvements.
Market read
Traders can update Q4 expectations for Sterigenics and Nordion based on management’s directional commentary, while using reaffirmed 2026 guidance and leverage improvement to frame downside risk.
What to watch
Margin improvement at Nordion and improved net leverage (2.9x) could be underweighted versus the revenue decline; also, Sterigenics capacity and ethylene oxide upgrades may support later-year normalization.
Background
The piece summarizes Sotera Health’s Q3 earnings call, including segment demand commentary, Nordion shipment timing, cash flow/leverage, and litigation scheduling.
Ticker impact
Sotera Health guided 2026 revenue and EBITDA while updating Q4 growth expectations for Sterigenics and Nordion shipment timing.
Likely modest downside bias as investors weigh weaker sequential Sterigenics growth and Nordion revenue decline against reaffirmed full-year targets and improved margins.
The article provides specific Q4 directional commentary (Sterigenics not expecting normal sequential growth, Nordion revenue down on shipment timing) plus reaffirmed full-year guidance and leverage improvement, which should temper but not eliminate near-term concerns.
Market effects
Sterilization and radiopharma-adjacent services demand signals, especially Europe medical-device softness, may influence peers’ near-term demand expectations.
Europe customer softness is highlighted as the driver, suggesting regional demand divergence versus the U.S.
Shipment-timing dynamics in cobalt-60 harvest schedules underscore operational variability that can affect broader supply-chain expectations.
Counterpoint
Reaffirmed 2026 constant-currency revenue and adjusted EBITDA guidance suggests the softness may be more timing-related than structural, limiting downside beyond Q4.
Key entities
- companySotera Health
NASDAQ-listed sterilization and laboratory testing provider, subject of the earnings-call update.
- business_segmentSterigenics
Outsourced sterilization segment referenced for Q4 sequential growth expectations.
- business_segmentNelson Labs
Laboratory testing segment with revenue growth and margin commentary.
- business_segmentNordion
Cobalt-60-related revenue and margin performance discussed, including shipment timing effects.
- credit_rating_agencyMoody’s
Upgraded Sotera Health’s credit rating in early October, supporting leverage narrative.



